Mast cells have been implicated in several types of cardiac
and vascular dysfunction. Mast cells are
thought to contribute to rupture of atherosclerotic plaques by mediator
release. They are found around blood
clots in the body. Mast cells may
destabilize them and mature them by releasing heparin and degrading fibrinogen
with tryptase. Increased numbers of mast cells are associated with coronary
vasospasm.
Mast cell mediator levels are often higher in vascular and
cardiac events. In patients who die from
coronary heart disease, the histamine concentration in the coronary artery than
in control subjects. Higher white blood
cell, platelet and plasma histamine levels are found in patients with
peripheral vascular disease. Increased histamine levels are found in patients
with both stable coronary artery disease and acute coronary syndrome. Plasma histamine is elevated in the great
cardiac vein of 8/11 patients with variant angina.
One study found that tryptase is higher in patients without
acute coronary syndrome undergoing catheterization, compared to patients with
and without obstructive coronary disease.
In this study, patients in the highest 25% of tryptase values had 4.3x
greater risk for coronary artery disease.
Tryptase is being investigated as a marker to identify asymptomatic
patients with coronary artery disease and to track efficacy of treatment.
Mast cell mediators are also elevated in non-allergic
coronary events, indicating that there is a common pathway for both allergic (Kounis
syndrome) and non-allergic cardiac episodes.
Two cholesterol lowering medications, cervistatin and atorvastatin, inhibit
stem cell factor (SCF) mediated differentiation of mast cells. Lovastatin inhibited IgE-mediated
degranulation.
References:
Ribatti D, Crivellato E. Mast cells, angiogenesis, and
tumour growth. Biochim. Biophys. Acta Mol. Basis Dis. 2012 Jan; 1822(1):2-8.
Glowacki J, Mulliken JB. Mast cells in hemangioma and
vascular malformations. Pediatrics 1982; 70(1):48-51.
Kolck UW, Alfter K, Homann J, von Kügelgen I, Molderings GJ.
Cardiac mast cells: implications for heart failure. JACC 2007 Mar 13;
49(10):1106-1108.
Biteker M. Current
understanding of Kounis Syndrome. Expert
Rev Clin Immunol 2010 Sep;6(5):777-88.
No comments:
Post a Comment